Multi-institutional investigation: Biomarker identification for proper use of Nivolmab for head and neck cancer.

Multi-institutional investigation: Biomarker identification for proper use of Nivolmab for head and neck cancer. - Multi-institutional investigation: Biomarker identification for proper use of Nivolmab for head and neck cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036976

Enrollment

100

Registered

2019-06-05

Start date

2018-08-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with recurrent or metastatic head and neck cancer who recieved Nivolmab

Exclusion criteria

Exclusion criteria: Patient without the history of treatment of the chemotherapy including the platinum Patient who received Nivolmab as adjuvant chemotherapy The patient who received a combination with other anti-cancer agents

Design outcomes

Primary

Measure	Time frame
Identification of a new biomarker of Nivolmab for head and neck cancer.	—

Countries

Japan

Contacts

Public ContactKazuchika Ohno

Tokyo Medical and Dental University Department of Head and Neck Surgery

ohno.hns@tmd.ac.jp03-5803-5913

Outcome results